Description générale
Hydroxycarbamide (also known as hydroxyurea) is an antineoplastic antimetabolite used in treatment protocols for chronic myeloproliferative disorders, and in the management of sickle cell disease.
INN
Hydroxycarbamide
Codes ATC
Type de médicament
Chemical agent
Historique des statuts LME
Ajouté pour la première fois en 2009
(TRS
958)
pour
Chronic myeloid leukaemia, not elsewhere classified
Ajouté en 2009
(TRS
958)
pour
Squamous cell carcinoma of oropharynx
Ajouté en 2011
(TRS
965)
pour
Other specified sickle cell disorders or other haemoglobinopathies
Retiré en 2015
(TRS
994)
pour
Squamous cell carcinoma of oropharynx
Wikipédia
DrugBank
Recommandations
Section
Cytotoxic medicines
- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Section
Other medicines for haemoglobinopathies
- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg